Objectives: We conducted a multicenter phase II study to evaluate the clinical efficacy, toxicity, and dose intensity of a new weekly schedule of docetaxel and gemcitabine as first-line treatment of metastatic breast cancer patients. Methods: We enrolled 58 patients, 52% of whom had received a previous anthracycline-containing chemotherapy. The treatment schedule was: docetaxel 35 mg/m2 and gemcitabine 800 mg/m2 i.v. on days 1, 8, 15 every 28 days. Results: All patients were assessable for toxicity and 56 for efficacy. Overall response rate was 64.3% with 16.1% of complete responses and 48.2% of partial responses. Median survival was 22.10 months (95% CI: 15.53–28.67) and median time to tumor progression was 13.6 months (95% CI: 10.71–16.49). The most common hematological toxicity was neutropenia (no febrile neutropenia), which occurred in 28 patients (48.3%) but grade 3–4 in only 8 patients (14%). Alopecia, the most common nonhematological toxicity, occurred in 20 (34.5%) patients, but only 5 patients (8.6%) experienced grade 3 alopecia. Conclusion: The activity of docetaxel and gemcitabine in metastatic breast cancer is confirmed. The promising results of the employed schedule, in agreement with other published studies, need to be further confirmed within a phase III study.

1.
Henderson IC: Chemotherapy for metastatic disease; in Harris JR, Hellman S, Henderson JC, et al (eds): Breast Diseases. Philadelphia, Lippincott, 1991, pp 604–665.
2.
Valero V: Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy. Semin Oncol 1997;24:S13–S18.
3.
Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 1995;13:2643–2655.
4.
Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879–2885.
5.
Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886–2894.
6.
Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212–1219.
7.
Climent MA, Ruiz A, Llombart-Cussac A, Fernandez-Martos C, Poveda A, Dorta J, Guillem V: Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results (abstract 453). Proc Am Soc Clin Oncol 1999;18:119.
8.
Loeffler TM, Droege C, Hausamen TU, et al: Dose-dense weekly docetaxel (Taxotere) in metastatic breast cancer (abstract). Breast Cancer Res Treat 1999;57:125.
9.
Ramos M, Gonzalez-Ageitos A, Vicente J: Weekly docetaxel (D) for metastatic breast cancer (MBC) progressing after anthracycline treatment (abstract 445). Proc Am Soc Clin Oncol 2000;19:155.
10.
Hainsworth JD, Burris HA 3rd, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500–3505.
11.
Stemmler HJ, Gutschow K, Sommer H, Malekmohammadi M, Kentenich CH, Forstpointner R, Geuenich S, Bischoff J, Hiddemann W, Heinemann V: Weekly docetaxel (taxotere) in patients with metastatic breast cancer. Ann Oncol 2001;12:1393–1398.
12.
Aihara T, Kim Y, Takatsuka Y: Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002;23:286–292.
13.
Climent MA, Tabernero J, Albanell J, Lluch A, Vermorken J, Barnadas A, Anton A, Laurent C, Mayordomo JI, Vazquez-Estevez S, Constenla M, Dirix LY, Losa I, Tisaire JL, Guillem V, Garcia-Conde J, Baselga J: Preliminary results of a phase II randomized trial of docetaxel (taxotere) as a single agent chemotherapy (CT) administered weekly or 3-weekly in patients (pts) with metastatic breast cancer (MBC) (abstract 205). Proc Am Soc Clin Oncol 2002;21:52a.
14.
Silvestris N, Di Cosimo S, Locopo N, D’Aprile M, Lorusso V: Rationale for the use of gemcitabine in treating breast cancer. Trends Med 2003;3:163–173.
15.
Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer :a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731–2736.
16.
Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 2002;62:2–8.
17.
Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001;60:303–307.
18.
Ferrari S, Danova M, Palmeri S, Brugnatelli S, Tamburo De Bella M, Porta C, Riccardi A: Apoptosis and cell cycle perturbation induced by docetaxel + gemcitabine in MCF7 breast cancer cells (abstract 330). Proc 25th Annu Meet Ital Assoc Med Oncol, Rome, 1999, p 109.
19.
Brugnatelli S, Danova M, Tamburo De Bella M, Vaglica M, Manuguerra G, Riccardi A, Palmeri S: Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: A phase 1 study. Oncology 2002;62:33–38.
20.
Palmeri S, Vaglica M, Accurso V, Gebbia V, Vassallo E, Danova M, Vetri G, Farris A, Mangiameli A, Manuguerra G, Filippelli G, Lorusso V: Weekly docetaxel (doc) + gemcitabine (gem) as first line therapy for advanced breast cancer (ABC): A multicenter phase II study (abstract 1991). Proc Am Soc Clin Oncol 2002;21:456.
21.
Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 1981;47:207–214.
22.
Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J for the 303 Study Group: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341–2354.
23.
Ravdin P, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba W, Olsen S, Meyers ML, Jones S: Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC) (abstract 670). ECCO 12, Eur J Cancer 2003;1(suppl 5):S201.
24.
Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A and Aapro M for the 304 Study Group: Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999;17:1413–1424.
25.
Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson N-O, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194–1201.
26.
Zimatore M, Danova M, Vassallo E, Porta C, Macaluso MC, Schittone L, Riccardi A, Palmeri S: Weekly taxanes in metastatic breast cancer (review). Oncol Rep 2002;9:1047–1052.
27.
Mavroudis D, Malamos N, Alexapoulos A, Kourousis Ch, Agelaki S, Sarra E, Potamianou A, Kosmas Ch, Rigatos G, Giannakakis Th, Kalbakis K, Apostolaki F, Vlachonicolis J, Kakolyris S, Samonis G, Georgoulias V: Salvage chemotherapy in anthracycline-pretreated patients with docetaxel and gemcitabine: A multicenter phase II trial. Ann Oncol 1999;10:211–215.
28.
Pelegri A, Calvo L,Mayordomo JI, Anton A, Florian J, Vazquez S, Arcusa A, Martin-Richard M, Bayo JL, Virizuela J, Carrasco E, Anton A: Gemcitabine and docetaxel given every 2 weeks as first-line therapy for metastatic breast cancer (MBC): Preliminary results from a phase II trial. Semin Oncol 2004;31(suppl 5):20–24.
29.
Mavroudis D, Malamos N, Polyzos K, Kalbakis K, Karyda E, Alexapoulos A, Cristophylakis C, Tzaninis D, Kouroussis C, Agelaki S: A multicenter phase II study of docetaxel plus gemcitabine biweekly administration as first line treatment in patients with metastatic breast cancer (MBC) (abstract 259). Proc Am Soc Clin Oncol 2003;22:65.
30.
Garle PA, Calvo L, Mayordomo J I, Anton A, Florian J, Vazquez S, Arcusa A, Martin-Richard M, Bayo JL, Carrasco E: Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer (MBC): Final results of a phase II study conducted within the Breast Cancer Investigation Spanish Group (GEICAM) (abstract 201). Proc Am Soc Clin Oncol 2003;22:50.
31.
Fountzilas G, Nicolaides C, Bafaloukos D, Kalogera-Fountzila A, Kalofonos H, Samelis G, Aravantinos G, Pavlidis N: Docetaxel and Gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic Cooperative Oncology Group phase II study. Cancer Invest 2000;18:503–509.
32.
Laufman LR, Spiridonidis CH, Pritchard J, Roach R, Zangmeister J, Larrimer N, Moore T, Segal M, Jones J, Patel T, Gutterman L, Carman L, Colborn D, Kuebler JP: Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial. Ann Oncol 2001;12:1259–1264.
33.
Kornek GV, Haider K, Kwasny W, Raderer M, Schull B, Payrits T, Depisch D, Kovats E, Lang F, Scheithauer W: Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 2002;8:1051–1056.
34.
Alexopoulos A, Tryfonopoulos D, Karamouzis MV, Gerasimidis G, Karydas I, Kandilis K, Stavrakakis J, Stavrinides H, Georganta C, Ardavanis A, Rigatos G: Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 2004;15:95–99.
35.
Brandi M, Vici P, Lopez M, Valerio MR, Giotta F, Gebbia N, Schittulli F, Colucci G; Gruppo Oncologico Italia Meridionale: novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 2004;31(suppl 5):13–19.
36.
Slee PH, De Jong RS, Honkoop Arodenburg C, Rooda SE, Coenen J, De Jong PC, Douma J: Combination chemotherapy with docetaxel and gemcitabine in anthracycline pretreated patients with metastatic breast cancer (MBC) (abstract 792). Proc Am Soc Clin Oncol 2004;23:145.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.